Samsung partners with Alcedis to use wearable tech in clinical trials
三星與 Alcedis 合作，將穿戴式技術應用於臨床試驗
更新於: 2026年6月24日 上午09:00
On June 24, 2026, Samsung Electronics unveiled a strategic partnership with Alcedis, a German clinical research organization, to revolutionize how new drugs are developed.
2026年6月24日，三星電子宣布與德國臨床研究組織Alcedis建立戰略合作夥伴關係，旨在徹底改革新藥開發方式。
By integrating Samsung’s advanced wearable technology into clinical trials, the companies aim to transition research away from hospital-centric models toward decentralized clinical trials (DCT).
透過將三星先進的可穿戴技術整合至臨床試驗中，兩家公司計畫將研究模式從以醫院為中心，轉向去中心化臨床試驗(DCT)。
The initiative focuses on using data from the Galaxy Watch to provide continuous, real-world health insights.
該計畫聚焦於利用Galaxy Watch的數據，提供持續且真實世界的健康洞察。
Samsung provides the hardware and sensor infrastructure, including sophisticated biosensors like Bioelectrical Impedance Analysis (BIA) and Electrodermal Activity (EDA), alongside software for monitoring conditions such as sleep apnea and atrial fibrillation.
三星提供硬體與感測器基礎設施，包括複雜的生物感測器，如生物電阻抗分析(BIA)與皮膚電活動(EDA)，以及用於監測睡眠呼吸中止症與心房顫動等狀況的軟體。
By shifting to this data-driven approach, researchers can reduce the burden of frequent hospital visits for patients, improve the reliability of data, and ultimately accelerate the pace of medical innovation.
透過轉向這種數據導向的方法，研究人員能減輕患者頻繁前往醫院的負擔，提升數據的可靠性，並最終加速醫療創新的步伐。
This partnership marks a significant step toward a more efficient, patient-centric future for clinical research and healthcare.
此項合作標誌著臨床研究與醫療保健邁向更高效、以患者為中心的未來，邁出了重要的一步。
